Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 update, outlining plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics targeting EGFR-mutated lung cancer and other cancers. The company stated that CL-741 would complement its existing portfolio, which includes ENV-105, KROS-201, KROS-102, and ENV-205.
Looking ahead, Kairos expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings, and pursue pharmaceutical collaborations. The company also noted it has secured more than $8 million in non-dilutive funding to support development of its preclinical and clinical programs.
Based in Los Angeles, California, Kairos Pharma Ltd. is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
For more information, the full press release is available at https://ibn.fm/WuBOf. The latest news and updates relating to KAPA can be found in the company’s newsroom at https://ibn.fm/KAPA.